The prevalence and surgical outcome of late diagnosed hip dysplasia in children with Prader-Willi syndrome: a retrospective study

Prader-Willi综合征患儿晚期诊断髋关节发育不良的患病率和手术结果:一项回顾性研究

阅读:1

Abstract

BACKGROUND: Prader-Willi syndrome (PWS) is a rare disease. Hip dysplasia is an orthopedic-related disease of PWS. Limited literature exists on the prevalence, diagnosis, and surgical management of late diagnosed hip dysplasia in PWS. This study assessed the prevalence of hip dysplasia in children with PWS and evaluated the outcomes following surgical intervention of late diagnosed hip dysplasia. METHODS: A retrospective analysis was conducted on patients diagnosed with PWS at our institution from January 1, 2017 to December 31, 2021. Patient demographics were collected, the acetabular index (AI) and the central edge angle (CEA) were measured. A single fellowship-trained pediatric orthopedic surgeon determined the presence of hip dysplasia based on radiographic measurements. RESULTS: The prevalence of hip dysplasia with PWS is 33.3%. There was no significant association between prevalence and sex or genetic subtype. The mean age at the time of diagnosis was 34.4 months (6 months to 109 months). Five patients (2 right side, 3 bilateral) underwent surgical intervention at an average age of 82.4 months. The acetabular index decreased from 42.8 ± 5.9 degrees preoperatively to 21.7 ± 7.7 degrees postoperatively. No serious postoperative complications were reported during the follow-up. CONCLUSIONS: The present study demonstrated a higher prevalence of hip dysplasia in patients with PWS than in the general population. The prevalence does not significantly differ across sexes or genetic subtypes. While preliminary findings suggest outcomes may be comparable to those of HD without PWS, further studies with larger cohorts are required to validate these observations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。